Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Commentary

Strength and Clarity of Vaccine Recommendations Influence Providers’ Practice

Michael T. Brady
Pediatrics September 2018, 142 (3) e20181633; DOI: https://doi.org/10.1542/peds.2018-1633
Michael T. Brady
Infectious Diseases, Nationwide Children’s Hospital, Columbus, Ohio; and The Ohio State University, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • Comments
Loading
Download PDF
  • Abbreviation:
    MenB —
    meningococcal serogroup B
  • In 2015, 2 meningococcal serogroup B (MenB) vaccines were licensed by the US Food and Drug Administration for persons ≥10 years through 25 years of age through an accelerated approval process.1 The Advisory Committee on Immunizations Practices recommended MenB vaccines for adolescents and young adults not at increased risk for meningococcal B disease using a new recommendation designation, Category B, defined as a recommendation for individual clinical decision-making.2,3 The Centers for Disease Control and Prevention and the American Academy of Pediatrics acknowledged issues that remained because of the accelerated approval.2,4 Duration of immunity, effectiveness of a newly structured meningococcal vaccine (ie, outer membrane protein antigens rather than conjugated polysaccharide antigens), long-term adverse effects, and the proportion of meningococcal B strains that would be covered by the 2 vaccines had yet to be established.3,4

    In this month’s issue of Pediatrics,5 results from a survey of pediatricians and family physicians were used to provide insight as to how providers might discuss and recommend MenB vaccines. The survey was used to query providers to assess factors influencing their plans to discuss and recommend MenB vaccines. Awareness of meningococcal B college outbreaks increased the likelihood of discussing and recommending the MenB vaccine. Factors that also enhanced providers’ likelihood of recommending the MenB vaccine were as follows: (1) the incidence of serogroup B meningococcal disease and (2) effectiveness and safety of the MenB vaccines. It is apparent why outbreak awareness would positively influence the decision to discuss and recommend MenB vaccines. However, the incidence of MenB disease has declined by more than 90% in the past 2 decades,6 and the effectiveness and long-term safety of the MenB vaccines have not yet been established.2 These factors should have actually diminished the likelihood for providing a strong recommendation for MenB vaccines. Providers were also more likely to discuss and recommend the MenB vaccines for their patients entering college. This occurred despite the fact that there were no data at the time of the survey to support an increased risk of meningococcal B disease in college students.3 Knowledge of meningococcal B college outbreaks and evidence of increased meningococcal C and Y disease in college students7 likely influenced their responses.

    The Category B recommendation that called for individual decision-making was the factor most likely to reduce rather than increase the administration of this vaccine. However, time to discuss a Category B recommendation was stated as not being an impediment to discussing or recommending the MenB vaccines. This response might actually reflect how providers would want things to be if time during a routine visit was not limited. Given the time available during a routine visit, pediatricians must prioritize what needs to be discussed. When pediatricians are fortunate to have 16- to 18-year-old patients come to a routine visit, there are many important issues to discuss, such as sexual activity, tobacco, alcohol and illicit drug use, contraception, and mental health. Pediatricians have strongly advocated for routinely recommended vaccines, resulting in high immunization rates even in adolescents. But given the limited opportunities for providers to see a 16- to 18-year-old, and with all of the important issues to be discussed, it is suggested in the survey results that this new recommendation of “may be given” impacts providers’ fervor about how they would discuss and recommend the MenB vaccines. Responses varied considerably concerning willingness to discuss and recommend the MenB vaccines. Without specific and clear guidance as to how to quantify benefits, risks, and costs for their individual patients, it is easy to understand why providers would have disparate responses reflecting the challenge associated with a new vaccine and a new vaccine recommendation classification.

    The proportion of adolescents who have received MenB vaccines at the time of the survey was markedly lower than might be expected by survey responses, and many of the responses were counter to available information. It is possible, and even likely, that the survey responses represent what the responders would want to do rather than what they were actually doing. This may be a limitation of all surveys. Additionally, low MenB immunization rates may reflect the difficulty of getting 16- to 18-year-old patients in for a routine visit.

    Pediatricians appreciate recommendations that are evidence based, clear, and unequivocal. When this is the case, they have been responsible for achieving exceptional immunization rates, even in adolescents. Rates for routinely recommended vaccines in adolescents far exceed those achieved for the MenB vaccine and the initial permissive human papillomavirus recommendation for boys8 (tetanus, diphtheria, and acellular pertussis vaccine: 88%; quadrivalent meningococcal conjugate vaccine [MCV4] first dose: 82%; and second dose: 39%).9 Recommendations that require clinical decision-making need to provide clear guidance that informs providers so that they can determine what needs to be discussed with their patients and families and determine how strongly to recommend the vaccine. Without this guidance, providers will continue to be challenged with Category B or permissive recommendations as suggested in the survey.

    Footnotes

      • Accepted May 30, 2018.
    • Address correspondence to Michael T. Brady, MD, Infectious Diseases, Nationwide Children’s Hospital, 700 Children’s Dr, J5421, Columbus, OH 43205. E-mail: michael.brady{at}nationwidechildrens.org
    • Opinions expressed in these commentaries are those of the author and not necessarily those of the American Academy of Pediatrics or its Committees.

    • FINANCIAL DISCLOSURE: Dr Brady receives a royalty from Up-To-Date for a chapter on human herpesvirus 6.

    • FUNDING: No external funding.

    • POTENTIAL CONFLICT OF INTEREST: The author has indicated he has no potential conflicts of interest to disclose.

    • COMPANION PAPER: A companion to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2018-0344.

    References

    1. ↵
      1. Food and Drug Administration
      . Accelerated approval of new drugs for serious or life-threatening illnesses, 21 C.F.R. Sect. 314.500. 2015. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.8. Accessed June 29, 2018
    2. ↵
      1. MacNeil JR,
      2. Rubin L,
      3. Folaranmi T,
      4. Ortega-Sanchez IR,
      5. Patel M,
      6. Martin SW
      . Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–1176pmid:26492381
      OpenUrlCrossRefPubMed
    3. ↵
      1. Ahmed F
      . US Advisory Committee on Immunizations Practices Handbook for Developing Evidence-Based Recommendations. Version 1.2. Atlanta, GA: CDC; 2013
    4. ↵
      1. American Academy of Pediatrics Committee on Infectious Diseases
      . Recommendations for serogroup B meningococcal vaccine for persons 10 years and older. Pediatrics. 2016;138:(3):20161890
      OpenUrl
    5. ↵
      1. Kempe A,
      2. Allison MA,
      3. MacNeil JR, et al
      . Adoption of serogroup B meningococcal vaccine recommendations. Pediatrics. 2018;142(3):e20180344
      OpenUrlAbstract/FREE Full Text
    6. ↵
      1. Meyer S; Centers for Disease Control and Prevention (CDC)
      . Update on the epidemiology of meningococcal disease and guidance for the control of meningococcal disease outbreaks in the U.S. Presented at: Meeting of the Advisory Committee on Immunization Practices (ACIP); February 22–23, 2017; Atlanta, GA
    7. ↵
      1. Bilukha OO,
      2. Rosenstein N; CDC
      . Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR–7):1–21
      OpenUrlPubMed
    8. ↵
      1. Centers for Disease Control and Prevention (CDC)
      . National and state vaccination coverage among adolescents aged 13-17 years–United States, 2011 [published correction appears in MMWR Morb Mortal Wkly Rep. 2012;61(41):844]. MMWR Morb Mortal Wkly Rep. 2012;61(34):671–677pmid:22932301
      OpenUrlPubMed
    9. ↵
      1. Walker TY,
      2. Elam-Evans LD,
      3. Singleton JA, et al
      . National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(33):874–882pmid:28837546
      OpenUrlCrossRefPubMed
    • Copyright © 2018 by the American Academy of Pediatrics
    PreviousNext
    Back to top

    Advertising Disclaimer »

    In this issue

    Pediatrics
    Vol. 142, Issue 3
    1 Sep 2018
    • Table of Contents
    • Index by author
    View this article with LENS
    PreviousNext
    Email Article

    Thank you for your interest in spreading the word on American Academy of Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Strength and Clarity of Vaccine Recommendations Influence Providers’ Practice
    (Your Name) has sent you a message from American Academy of Pediatrics
    (Your Name) thought you would like to see the American Academy of Pediatrics web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Request Permissions
    Article Alerts
    Log in
    You will be redirected to aap.org to login or to create your account.
    Or Sign In to Email Alerts with your Email Address
    Citation Tools
    Strength and Clarity of Vaccine Recommendations Influence Providers’ Practice
    Michael T. Brady
    Pediatrics Sep 2018, 142 (3) e20181633; DOI: 10.1542/peds.2018-1633

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Strength and Clarity of Vaccine Recommendations Influence Providers’ Practice
    Michael T. Brady
    Pediatrics Sep 2018, 142 (3) e20181633; DOI: 10.1542/peds.2018-1633
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Print
    Download PDF
    Insight Alerts
    • Table of Contents

    Jump to section

    • Article
      • Footnotes
      • References
    • Info & Metrics
    • Comments

    Related Articles

    • No related articles found.
    • PubMed
    • Google Scholar

    Cited By...

    • No citing articles found.
    • Google Scholar

    More in this TOC Section

    • Ensuring the Safety of Maternal Immunization
    • Evaluating Intersectionality of Policies and Populations
    • Safety of Breastfeeding by Mothers With COVID-19: New Evidence From Israel
    Show more Commentaries

    Similar Articles

    Subjects

    • Infectious Disease
      • Infectious Disease
      • Vaccine/Immunization
    • Journal Info
    • Editorial Board
    • Editorial Policies
    • Overview
    • Licensing Information
    • Authors/Reviewers
    • Author Guidelines
    • Submit My Manuscript
    • Open Access
    • Reviewer Guidelines
    • Librarians
    • Institutional Subscriptions
    • Usage Stats
    • Support
    • Contact Us
    • Subscribe
    • Resources
    • Media Kit
    • About
    • International Access
    • Terms of Use
    • Privacy Statement
    • FAQ
    • AAP.org
    • shopAAP
    • Follow American Academy of Pediatrics on Instagram
    • Visit American Academy of Pediatrics on Facebook
    • Follow American Academy of Pediatrics on Twitter
    • Follow American Academy of Pediatrics on Youtube
    • RSS
    American Academy of Pediatrics

    © 2021 American Academy of Pediatrics